Principia Biopharma, Inc.. (PRNB) NASDAQ
$100.05 0 (0.00%)
Market Cap: $3.32B
As of 09/25/20 12:00 AM EDT. Market closed.
Principia Biopharma, Inc.. (PRNB)
NASDAQ
$100.05
0 (0.00%)
Market Cap: $3.32B
As of 09/25/20 12:00 AM EDT. Market closed.
Principia Biopharma, Inc. is a biopharmaceutical company, which engages in designing and developing oral therapies to patients with significant unmet medical needs in immunology and oncology. It operates through Tailored Covalency platform, which enables to develop small molecule inhibitors of enzymes and receptor ligands with potencies and selectivities that rival those of injectable biologics, ... read more
Principia Biopharma, Inc. is a biopharmaceutical company, which engages in designing and developing oral therapies to patients with significant unmet medical needs in immunology and oncology. It operates through Tailored Covalency platform, which enables to develop small molecule inhibitors of enzymes and receptor ligands with potencies and selectivities that rival those of injectable biologics, yet maintain the convenience of a pill. Its product pipeline includes PRN1008, PRN2246, PRN1371, and immunoproteasome inhibitor. The company was founded by Jack Taunton and Richard A. Miller on October 6, 2008 and is headquartered in South San Francisco, CA. read less
COMPANY PROFILE
Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Martin Babler
Full Time Employees
103
CEO Compensation (Base)
$447,128
CEO Compensation (Total)
$2.32M
Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Martin Babler
Full Time Employees
103
CEO Compensation (Base)
$447,128
CEO Compensation (Total)
$2.32M
Address
220 East Grand Avenue, CA, South San Francisco, 94080.
PRICE CHART FOR PRINCIPIA BIOPHARMA, INC.
From:
To:
NEWS
KEY STATS
Open
$0
Previous Close
$100.05
Days Range
$0 - $0
52 week range
$25.35 - $101.89
Volume
0
Avg. Volume (30 days)
2,469,813
Market Cap
$3.32B
Dividend Yield
0.00%
P/E
-
Shares Outstanding
33,208,500
Open
$0
Previous Close
$100.05
Days Range
$0 - $0
52 week range
$25.35 - $101.89
Volume
0
Avg. Volume (30 days)
2,469,813
Market Cap
$3.32B
Dividend Yield
0.00%
P/E
-
Shares Outstanding
33,208,500
Open in: 
Open in:
INSIDER TRANSACTIONS FOR PRINCIPIA BIOPHARMA, INC.
| Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
| George Simeon | Director | Sep 28, 2020 | Option Exercise | $100.00 | 2,982,855 | 298,285,500 | 0 | Sep 28, 2020, 05:27 PM |
| Becker Daniel J. | Director | Sep 28, 2020 | Option Exercise | $100.00 | 667,600 | 66,760,000 | 0 | Sep 28, 2020, 05:24 PM |
| Wolff Stefani | Chief Development Officer | Sep 28, 2020 | Option Exercise | $100.00 | 13,592 | 1,359,200 | 0 | Sep 28, 2020, 05:19 PM |
| Thomas Dolca | Chief Medical Officer | Sep 28, 2020 | Option Exercise | $100.00 | 2,207 | 220,700 | 0 | Sep 28, 2020, 05:16 PM |
| Hardiman Roy C. | Chief Business Officer | Sep 28, 2020 | Option Exercise | $100.00 | 1,916 | 191,600 | 0 | Sep 28, 2020, 05:14 PM |
| Hardiman Roy C. | Chief Business Officer | Sep 28, 2020 | Option Exercise | $100.00 | 117,761 | 11,776,100 | 0 | Sep 28, 2020, 05:14 PM |
| CHAI CHRISTOPHER Y | Chief Financial Officer | Sep 28, 2020 | Option Exercise | $100.00 | 3,302 | 330,200 | 0 | Sep 28, 2020, 05:11 PM |
| CHAI CHRISTOPHER Y | Chief Financial Officer | Sep 28, 2020 | Option Exercise | $100.00 | 3,799 | 379,900 | 0 | Sep 28, 2020, 05:11 PM |
| Goldstein David M | Chief Scientific Officer | Sep 28, 2020 | Option Exercise | $100.00 | 31,826 | 3,182,600 | 0 | Sep 28, 2020, 05:08 PM |
| Babler Martin | President, CEO | Sep 28, 2020 | Option Exercise | $100.00 | 57,534 | 5,753,400 | 0 | Sep 28, 2020, 05:07 PM |
| Babler Martin | President, CEO | Sep 28, 2020 | Option Exercise | $100.00 | 1,023 | 102,300 | 0 | Sep 28, 2020, 05:07 PM |
| Hardiman Roy C. | Chief Business Officer | Sep 18, 2020 | Option Exercise | $5.86 | 5,000 | 29,321 | 122,761 | Sep 22, 2020, 08:02 PM |
| Hardiman Roy C. | Chief Business Officer | Sep 18, 2020 | Sale | $99.98 | 5,000 | 499,917 | 117,761 | Sep 22, 2020, 08:02 PM |
| Thomas Dolca | Chief Medical Officer | Aug 18, 2020 | Option Exercise | $23.77 | 15,000 | 356,550 | 16,826 | Aug 20, 2020, 08:17 PM |
| Thomas Dolca | Chief Medical Officer | Aug 18, 2020 | Sale | $100.00 | 15,000 | 1,500,000 | 1,826 | Aug 20, 2020, 08:17 PM |
| CHAI CHRISTOPHER Y | Chief Financial Officer | Aug 18, 2020 | Option Exercise | $3.00 | 7,500 | 22,483 | 11,039 | Aug 20, 2020, 08:01 PM |
| CHAI CHRISTOPHER Y | Chief Financial Officer | Aug 18, 2020 | Sale | $99.37 | 7,500 | 745,240 | 3,539 | Aug 20, 2020, 08:01 PM |
| Goldstein David M | Chief Scientific Officer | Aug 10, 2020 | Option Exercise | $3.11 | 6,000 | 18,632 | 37,739 | Aug 12, 2020, 08:01 PM |
| Goldstein David M | Chief Scientific Officer | Aug 10, 2020 | Sale | $88.61 | 6,000 | 531,665 | 36,881 | Aug 12, 2020, 08:01 PM |
| Thomas Dolca | Chief Medical Officer | Jul 15, 2020 | Option Exercise | $23.77 | 15,000 | 356,550 | 16,826 | Jul 17, 2020, 08:01 PM |
| Thomas Dolca | Chief Medical Officer | Jul 15, 2020 | Sale | $80.07 | 15,000 | 1,201,069 | 1,826 | Jul 17, 2020, 08:01 PM |
| Colowick Alan | Director | Jul 01, 2020 | Option Exercise | $4.54 | 7,500 | 34,065 | 7,500 | Jul 02, 2020, 08:48 PM |
| Colowick Alan | Director | Jul 01, 2020 | Sale | $60.00 | 7,500 | 450,000 | 0 | Jul 02, 2020, 08:48 PM |
| Babler Martin | President, CEO | Jun 23, 2020 | Option Exercise | $3.00 | 15,000 | 44,965 | 15,810 | Jun 25, 2020, 08:07 PM |
| Babler Martin | President, CEO | Jun 23, 2020 | Sale | $61.86 | 15,000 | 927,889 | 15,295 | Jun 25, 2020, 08:07 PM |
| Wolff Stefani | Chief Development Officer | Jun 15, 2020 | Sale | $60.75 | 5,504 | 334,385 | 24,200 | Jun 17, 2020, 09:52 PM |
| Wolff Stefani | Chief Development Officer | Mar 16, 2020 | Sale | $46.15 | 5,504 | 254,031 | 28,350 | Jun 17, 2020, 09:48 PM |
| Wolff Stefani | Chief Development Officer | Dec 16, 2019 | Sale | $49.43 | 5,505 | 272,091 | 31,404 | Jun 17, 2020, 09:41 PM |
| Hardiman Roy C. | Chief Business Officer | Jun 12, 2020 | Option Exercise | $4.72 | 5,000 | 23,618 | 122,761 | Jun 15, 2020, 08:12 PM |
| Hardiman Roy C. | Chief Business Officer | Jun 12, 2020 | Sale | $61.16 | 5,000 | 305,788 | 121,166 | Jun 15, 2020, 08:12 PM |
| CHAI CHRISTOPHER Y | Chief Financial Officer | May 19, 2020 | Option Exercise | $3.00 | 5,675 | 17,012 | 11,039 | May 21, 2020, 08:01 PM |
| CHAI CHRISTOPHER Y | Chief Financial Officer | May 19, 2020 | Sale | $65.10 | 7,500 | 488,268 | 3,539 | May 21, 2020, 08:01 PM |
| Goldstein David M | Chief Scientific Officer | May 07, 2020 | Option Exercise | $3.00 | 6,000 | 17,986 | 36,968 | May 08, 2020, 08:05 PM |
| Goldstein David M | Chief Scientific Officer | May 07, 2020 | Sale | $60.16 | 6,000 | 360,941 | 33,687 | May 08, 2020, 08:05 PM |
| Colowick Alan | Director | May 05, 2020 | Option Exercise | $4.54 | 6,660 | 30,250 | 6,660 | May 05, 2020, 08:07 PM |
| Colowick Alan | Director | May 01, 2020 | Option Exercise | $4.54 | 840 | 3,815 | 840 | May 05, 2020, 08:07 PM |
| Colowick Alan | Director | May 01, 2020 | Sale | $60.07 | 840 | 50,457 | 0 | May 05, 2020, 08:07 PM |
| Colowick Alan | Director | May 05, 2020 | Sale | $60.00 | 6,660 | 399,600 | 0 | May 05, 2020, 08:07 PM |
| Wolff Stefani | Chief Development Officer | Mar 16, 2020 | Option Exercise | $4.54 | 5,504 | 24,999 | 41,113 | Mar 18, 2020, 05:08 PM |
| Wolff Stefani | Chief Development Officer | Mar 16, 2020 | Sale | $46.15 | 5,504 | 254,031 | 39,359 | Mar 18, 2020, 05:08 PM |
| Hardiman Roy C. | Chief Business Officer | Mar 13, 2020 | Option Exercise | $4.72 | 5,000 | 23,618 | 121,903 | Mar 17, 2020, 05:08 PM |
| Hardiman Roy C. | Chief Business Officer | Mar 13, 2020 | Sale | $48.56 | 5,000 | 242,816 | 118,184 | Mar 17, 2020, 05:08 PM |
| Babler Martin | President, CEO | Mar 03, 2020 | Sale | $63.47 | 15,000 | 952,083 | 52,094 | Mar 05, 2020, 05:21 PM |
| CHAI CHRISTOPHER Y | Chief Financial Officer | Feb 18, 2020 | Option Exercise | $3.00 | 2,500 | 7,494 | 12,266 | Feb 20, 2020, 05:02 PM |
| CHAI CHRISTOPHER Y | Chief Financial Officer | Feb 18, 2020 | Sale | $65.89 | 7,500 | 494,186 | 9,582 | Feb 20, 2020, 05:02 PM |
| Goldstein David | Chief Scientific Officer | Feb 10, 2020 | Option Exercise | $3.00 | 6,000 | 17,986 | 36,968 | Feb 12, 2020, 07:03 PM |
| Goldstein David | Chief Scientific Officer | Feb 10, 2020 | Sale | $70.90 | 6,000 | 425,400 | 36,168 | Feb 12, 2020, 07:03 PM |
| Thomas Dolca | Chief Medical Officer | Dec 19, 2019 | Sale | $60.00 | 495 | 29,700 | 494 | Dec 20, 2019, 09:00 PM |
| Babler Martin | President, CEO | Dec 18, 2019 | Sale | $53.66 | 4,500 | 241,459 | 19,196 | Dec 19, 2019, 09:06 PM |
| Babler Martin | President, CEO | Dec 17, 2019 | Sale | $52.96 | 25,000 | 1,323,996 | 73,339 | Dec 19, 2019, 09:06 PM |
| Wolff Stefani | Chief Development Officer | Dec 16, 2019 | Option Exercise | $4.54 | 5,505 | 25,004 | 41,114 | Dec 18, 2019, 07:09 PM |
| Wolff Stefani | Chief Development Officer | Dec 16, 2019 | Sale | $49.43 | 5,505 | 272,091 | 36,909 | Dec 18, 2019, 07:09 PM |
| Hardiman Roy C. | Chief Business Officer | Dec 13, 2019 | Option Exercise | $4.95 | 5,000 | 24,743 | 125,143 | Dec 13, 2019, 08:04 PM |
| Hardiman Roy C. | Chief Business Officer | Dec 13, 2019 | Sale | $49.41 | 5,000 | 247,034 | 121,762 | Dec 13, 2019, 08:04 PM |
| Becker Daniel J. | Director | Nov 20, 2019 | Buy | $29.94 | 55,000 | 1,646,700 | 667,600 | Nov 22, 2019, 08:07 PM |
| Goldstein David | Chief Scientific Officer | Nov 07, 2019 | Option Exercise | $1.88 | 10,000 | 18,815 | 39,819 | Nov 08, 2019, 09:01 PM |
| Goldstein David | Chief Scientific Officer | Nov 07, 2019 | Sale | $32.39 | 10,000 | 323,914 | 29,819 | Nov 08, 2019, 09:01 PM |
| Becker Daniel J. | Director | Oct 29, 2019 | Buy | $33.98 | 9,196 | 312,477 | 612,600 | Oct 30, 2019, 04:16 PM |
| Becker Daniel J. | Director | Oct 28, 2019 | Buy | $33.41 | 68,404 | 2,285,549 | 603,404 | Oct 30, 2019, 04:16 PM |
| GLAXOSMITHKLINE PLC | Former 10% Owner | Oct 18, 2019 | Buy | $28.00 | 357,142 | 9,999,976 | 2,982,855 | Oct 22, 2019, 05:36 PM |
| George Simeon | Director | Oct 18, 2019 | Buy | $28.00 | 357,142 | 9,999,976 | 2,982,855 | Oct 22, 2019, 04:11 PM |
| Becker Daniel J. | Director | Oct 18, 2019 | Buy | $28.00 | 535,000 | 14,980,000 | 535,000 | Oct 22, 2019, 04:06 PM |
| New Leaf Ventures II, L.P. | 10% Owner | Aug 13, 2019 | Sale | $35.00 | 300,000 | 10,500,000 | 1,938,167 | Aug 15, 2019, 04:47 PM |
| ORBIMED ADVISORS LLC | 10% Owner | May 21, 2019 | Sale | $30.25 | 1,000,000 | 30,250,000 | 1,605,713 | May 22, 2019, 12:43 PM |
| Sofinnova Venture Partners VIII, L.P. | 10% Owner | Sep 18, 2018 | Buy | $17.00 | 270,000 | 4,590,000 | 2,038,208 | Sep 20, 2018, 07:02 PM |
| ORBIMED ADVISORS LLC | 10% Owner | Sep 18, 2018 | Buy | $17.00 | 250,000 | 4,250,000 | 2,605,713 | Sep 20, 2018, 06:59 PM |
| Becker Daniel J. | Director | Sep 18, 2018 | Buy | $17.00 | 270,000 | 4,590,000 | 437,537 | Sep 20, 2018, 06:58 PM |
| New Leaf Ventures II, L.P. | 10% Owner | Sep 18, 2018 | Buy | $17.00 | 270,000 | 4,590,000 | 437,537 | Sep 20, 2018, 06:53 PM |
| George Simeon | Director | Sep 18, 2018 | Buy | $17.00 | 270,000 | 4,590,000 | 2,625,713 | Sep 20, 2018, 06:50 PM |
| GLAXOSMITHKLINE PLC | 10% Owner | Sep 18, 2018 | Buy | $17.00 | 270,000 | 4,590,000 | 2,625,713 | Sep 20, 2018, 05:18 PM |
| AKKARAJU SRINIVAS | Director | Sep 18, 2018 | Buy | $17.00 | 175,000 | 2,975,000 | 383,480 | Sep 20, 2018, 04:14 PM |
Load More Insider Transactions
Buy
Sale
Option Exercise
| Owner | Relationship | Date | Value($) |
| George Simeon | Director | 09/28/2020 | 298,285,500 |
| Becker Daniel J. | Director | 09/28/2020 | 66,760,000 |
| Wolff Stefani | Chief Development Officer | 09/28/2020 | 1,359,200 |
| Thomas Dolca | Chief Medical Officer | 09/28/2020 | 220,700 |
| Hardiman Roy C. | Chief Business Officer | 09/28/2020 | 191,600 |
| Hardiman Roy C. | Chief Business Officer | 09/28/2020 | 11,776,100 |
| CHAI CHRISTOPHER Y | Chief Financial Officer | 09/28/2020 | 330,200 |
| CHAI CHRISTOPHER Y | Chief Financial Officer | 09/28/2020 | 379,900 |
| Goldstein David M | Chief Scientific Officer | 09/28/2020 | 3,182,600 |
| Babler Martin | President, CEO | 09/28/2020 | 5,753,400 |
| Babler Martin | President, CEO | 09/28/2020 | 102,300 |
| Hardiman Roy C. | Chief Business Officer | 09/18/2020 | 29,321 |
| Hardiman Roy C. | Chief Business Officer | 09/18/2020 | 499,917 |
| Thomas Dolca | Chief Medical Officer | 08/18/2020 | 356,550 |
| Thomas Dolca | Chief Medical Officer | 08/18/2020 | 1,500,000 |
| CHAI CHRISTOPHER Y | Chief Financial Officer | 08/18/2020 | 22,483 |
| CHAI CHRISTOPHER Y | Chief Financial Officer | 08/18/2020 | 745,240 |
| Goldstein David M | Chief Scientific Officer | 08/10/2020 | 18,632 |
| Goldstein David M | Chief Scientific Officer | 08/10/2020 | 531,665 |
| Thomas Dolca | Chief Medical Officer | 07/15/2020 | 356,550 |
| Thomas Dolca | Chief Medical Officer | 07/15/2020 | 1,201,069 |
| Colowick Alan | Director | 07/01/2020 | 34,065 |
| Colowick Alan | Director | 07/01/2020 | 450,000 |
| Babler Martin | President, CEO | 06/23/2020 | 44,965 |
| Babler Martin | President, CEO | 06/23/2020 | 927,889 |
| Wolff Stefani | Chief Development Officer | 06/15/2020 | 334,385 |
| Wolff Stefani | Chief Development Officer | 03/16/2020 | 254,031 |
| Wolff Stefani | Chief Development Officer | 12/16/2019 | 272,091 |
| Hardiman Roy C. | Chief Business Officer | 06/12/2020 | 23,618 |
| Hardiman Roy C. | Chief Business Officer | 06/12/2020 | 305,788 |
| CHAI CHRISTOPHER Y | Chief Financial Officer | 05/19/2020 | 17,012 |
| CHAI CHRISTOPHER Y | Chief Financial Officer | 05/19/2020 | 488,268 |
| Goldstein David M | Chief Scientific Officer | 05/07/2020 | 17,986 |
| Goldstein David M | Chief Scientific Officer | 05/07/2020 | 360,941 |
| Colowick Alan | Director | 05/05/2020 | 30,250 |
| Colowick Alan | Director | 05/01/2020 | 3,815 |
| Colowick Alan | Director | 05/01/2020 | 50,457 |
| Colowick Alan | Director | 05/05/2020 | 399,600 |
| Wolff Stefani | Chief Development Officer | 03/16/2020 | 24,999 |
| Wolff Stefani | Chief Development Officer | 03/16/2020 | 254,031 |
| Hardiman Roy C. | Chief Business Officer | 03/13/2020 | 23,618 |
| Hardiman Roy C. | Chief Business Officer | 03/13/2020 | 242,816 |
| Babler Martin | President, CEO | 03/03/2020 | 952,083 |
| CHAI CHRISTOPHER Y | Chief Financial Officer | 02/18/2020 | 7,494 |
| CHAI CHRISTOPHER Y | Chief Financial Officer | 02/18/2020 | 494,186 |
| Goldstein David | Chief Scientific Officer | 02/10/2020 | 17,986 |
| Goldstein David | Chief Scientific Officer | 02/10/2020 | 425,400 |
| Thomas Dolca | Chief Medical Officer | 12/19/2019 | 29,700 |
| Babler Martin | President, CEO | 12/18/2019 | 241,459 |
| Babler Martin | President, CEO | 12/17/2019 | 1,323,996 |
| Wolff Stefani | Chief Development Officer | 12/16/2019 | 25,004 |
| Wolff Stefani | Chief Development Officer | 12/16/2019 | 272,091 |
| Hardiman Roy C. | Chief Business Officer | 12/13/2019 | 24,743 |
| Hardiman Roy C. | Chief Business Officer | 12/13/2019 | 247,034 |
| Becker Daniel J. | Director | 11/20/2019 | 1,646,700 |
| Goldstein David | Chief Scientific Officer | 11/07/2019 | 18,815 |
| Goldstein David | Chief Scientific Officer | 11/07/2019 | 323,914 |
| Becker Daniel J. | Director | 10/29/2019 | 312,477 |
| Becker Daniel J. | Director | 10/28/2019 | 2,285,549 |
| GLAXOSMITHKLINE PLC | Former 10% Owner | 10/18/2019 | 9,999,976 |
| George Simeon | Director | 10/18/2019 | 9,999,976 |
| Becker Daniel J. | Director | 10/18/2019 | 14,980,000 |
| New Leaf Ventures II, L.P. | 10% Owner | 08/13/2019 | 10,500,000 |
| ORBIMED ADVISORS LLC | 10% Owner | 05/21/2019 | 30,250,000 |
| Sofinnova Venture Partners VIII, L.P. | 10% Owner | 09/18/2018 | 4,590,000 |
| ORBIMED ADVISORS LLC | 10% Owner | 09/18/2018 | 4,250,000 |
| Becker Daniel J. | Director | 09/18/2018 | 4,590,000 |
| New Leaf Ventures II, L.P. | 10% Owner | 09/18/2018 | 4,590,000 |
| George Simeon | Director | 09/18/2018 | 4,590,000 |
| GLAXOSMITHKLINE PLC | 10% Owner | 09/18/2018 | 4,590,000 |
| AKKARAJU SRINIVAS | Director | 09/18/2018 | 2,975,000 |
Load More Insider Transactions
CHANGE IN SHARES OUTSTANDING FOR PRINCIPIA BIOPHARMA, INC.
STOCK BUYBACKS FOR PRINCIPIA BIOPHARMA, INC.
Load More
Period of Report: 06/30/2020
10-K/10-Q Filings: View
Previous Period
% Change in Shares
Quarter
03/31/2020
0.14%
1Q
12/31/2019
28.17%
2Q
09/30/2019
38.03%
3Q
03/31/2019
38.44%
5Q
Load More